Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ALA in Pediatric High Grade Brain Tumours
NCT06678867Phase 2Not yet recruiting
- Sponsor
- University College London
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in brain tumor, sponsored by University College London. Primary endpoints: Complete resection rate of supratentorial intrinsic high grade brain tumours at 2 weeks and Fluorescence rate of tumours at 2 weeks. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
brain tumor
Beyond the preview
Go deeper on NCT06678867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678867.